China Medicine taps new CFO

> China Medicine has appointed Henry Chi Fung Ho as its CFO. Fred Cheung resigned from his position as CFO of China Medicine effective Nov. 16 to pursue other opportunities. China Medicine release

> China Sky One Medical has announced that Hong-yu Pan was appointed to serve as the company's CFO and treasurer, effective as of Nov. 19. China Sky One Medical release

> Acceleron Pharma's co-founder and CSO Jasbir Seehra has decided to leave the company to pursue other interests. He will maintain a consulting relationship with the company. Acceleron release

> Ablexis, a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative next-generation platform for antibody drug discovery, has appointed Sean Stevens as VP of research. Ablexis release

> Unigene Laboratories has named Jenene Thomas to the newly created position of VP of Investor Relations and Corporate Communications. Unigene release

> Hospira has named Francois (Frans) Dubois to the newly created position of senior VP, Quality, effective Jan. 3, 2011.  Hospira release

> Prolong Pharmaceuticals has formally added two pharmaceutical veterans to its senior management team. Richard Prince is now VP, Quality, and Andy Burger has assumed the title of VP, Information Services. Prolong release

> TranScrip Partners has appointed two new senior partners, Julia Lloyd-Parks and Mark Watling.  TranScrip release

> InQ Biosciences Corporation, a provider of innovative technologies for cell growth and research, announced that Michael Chambers and John Cooper have been appointed to the board of directors. InQ release

>  PolyMedix has announced that William DeGrado, Gregory Tew, Gill Diamond, Henry Heine and William Weiss are members of its scientific advisory board. PolyMedix release

> Amarin Corporation has named Kristine Peterson to its board of directors. Amarin release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.